Pharming Group Long Term Debt 2013-2024 | PHGUF

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Pharming Group long term debt from 2013 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Pharming Group long term debt from 2013 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$170.6B
Vertex Pharmaceuticals (VRTX)	$117.1B
Regeneron Pharmaceuticals (REGN)	$111.8B
Bristol Myers Squibb (BMY)	$109.9B
Gilead Sciences (GILD)	$104.8B
CSL (CSLLY)	$95.8B
GSK (GSK)	$79.5B
Alnylam Pharmaceuticals (ALNY)	$34.6B
Argenex SE (ARGX)	$32.5B
BioNTech SE (BNTX)	$28.5B
Biogen (BIIB)	$26.9B
Moderna (MRNA)	$23.5B
BeiGene (BGNE)	$22.7B
Illumina (ILMN)	$21.7B
Genmab (GMAB)	$15.5B
BioMarin Pharmaceutical (BMRN)	$12.9B
Incyte (INCY)	$12.9B
Vaxcyte (PCVX)	$12.4B
Exact Sciences (EXAS)	$12.3B
Insmed (INSM)	$12.3B
Bio-Techne Corp (TECH)	$11.7B
Sarepta Therapeutics (SRPT)	$11.3B
QIAGEN (QGEN)	$9.9B
Bio-Rad Laboratories (BIO.B)	$9.3B
Legend Biotech (LEGN)	$8.7B
Roivant Sciences (ROIV)	$8.3B
Ascendis Pharma (ASND)	$8.2B
Repligen (RGEN)	$7.8B
Revolution Medicines (RVMD)	$7.7B
Halozyme Therapeutics (HALO)	$7.7B